bluebird bio (NASDAQ:BLUE) is scheduled to release its earnings data after the market closes on Tuesday, February 20th. Analysts expect bluebird bio to post earnings of ($1.68) per share for the quarter.
Shares of bluebird bio (BLUE) opened at $213.35 on Friday. The firm has a market capitalization of $10,700.00, a PE ratio of -30.44 and a beta of 2.07. bluebird bio has a twelve month low of $73.95 and a twelve month high of $222.03.
In other bluebird bio news, insider Philip D. Gregory sold 2,250 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.54, for a total value of $388,215.00. Following the completion of the transaction, the insider now directly owns 28,734 shares of the company’s stock, valued at $4,957,764.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Davidson sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $202.36, for a total value of $809,440.00. The disclosure for this sale can be found here. Insiders sold 200,280 shares of company stock valued at $37,818,846 over the last three months. 3.90% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “bluebird bio (BLUE) to Release Quarterly Earnings on Tuesday” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/18/bluebird-bio-blue-to-release-quarterly-earnings-on-tuesday.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.